Navigation Links
Interim Analysis of Data from e-HEALING Registry of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
Date:11/7/2008

Sigmund Silber to Highlight 12-Month Patient Subset Results in Oral

Presentation

HONG KONG, Nov. 7 /PRNewswire/ -- An interim analysis of 12-month patient subset data from e-HEALING, a global post-marketing surveillance registry of OrbusNeich's Genous Bio-engineered R stent, will be presented next week at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans.

Sigmund Silber, M.D., F.A.C.C., F.E.S.C., a professor of medicine with the Cardiology Practice and Hospital, Munich, will present the data at 9:30 a.m. CST on Nov. 12 in Auditorium C at the Ernest N. Morial Convention Center. Silber and Robbert de Winter, M.D., Ph.D., F.E.S.C., a professor of medicine with the Academic Medical Center, Amsterdam, are the co-principal investigators of e-HEALING.

OrbusNeich's e-HEALING is a multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients treated with the Genous Bio-engineered R stent. The study protocol recommends that patients receive one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary endpoint of the registry is target vessel failure at 12 months.

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progeni
'/>"/>

SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
2. Misonix Announces Interim Distribution Agreement for Italy
3. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
4. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
5. Arpida Reports Interim Results for Six Months to 30 June 2008
6. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
7. LPBP Inc. - Re-filing certification of interim filings
8. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
9. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
10. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
11. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Global biostimulants market is expected to reach ... CAGR of 12.5%. In order to cater to ... ecological impacts, farmers are looking to adopt natural ... more effectively & efficiently. Biostimulants are consequently seen ... on investments. , Leading companies in the biostimulants ...
(Date:11/26/2014)... Dallas, Texas (PRWEB) November 26, 2014 ... Acid Industry is an in-depth research report on ... analysis, the report introduces Palmitic Acid, basic information, ... overview, policy analysis, and news analysis, etc. ... report analyzes Palmitic Acid market in ...
(Date:11/26/2014)... Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics ... of foodborne pathogens, today announced that Paul G. Thomas ... Annual Healthcare Conference on December 2, 2014 at 4:30pm ET. ... in New York, NY . ... operations, strategies and prospects may be discussed. To listen to ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 ... on developing diagnostic tests for cancer and other conditions, today ... be presented at the Science for Business BioWin Day 2014, ... . The data come from VolitionRx,s lung cancer pilot ... department of the Centre Hospitalier Universitaire (CHU) de Liege in ...
Breaking Biology Technology:2019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... , MILFORD, Mass., Dec. 9 ... it has shipped the first units of its ground-breaking SYNAPT(TM) ... American Society of Mass Spectrometry (ASMS) annual conference in Philadelphia ... research centers across Europe, North America and Asia and for ...
... , ... firm announces opening of its Brazilian regional office , ... Chicago, Ill. (Vocus) December 9, 2009 -- As ... globe, The Adventus Group, a world leader in the contaminated soil , sediment ...
... Dec. 8 Dendreon Corporation (Nasdaq: DNDN ) announced ... to market and other conditions, of 15,000,000 shares of its ... Dendreon intends to grant to the underwriters a 30-day ... common stock to cover over-allotments, if any. J. P. ...
Cached Biology Technology:Waters Ships First Units of SYNAPT G2 Mass Spectrometer 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4Dendreon Announces Proposed Public Offering of Common Stock 2Dendreon Announces Proposed Public Offering of Common Stock 3
(Date:11/5/2014)... show great diversity in their ability to identify scents ... differ in their perceptual evaluation of odors, with women ... , Sex differences in olfactory detection may play ... connected to one,s perception of smell, which is naturally ... superiority has been suggested to be cognitive or emotional, ...
(Date:11/4/2014)... (Philadelphia, PA) – Temple University School of Medicine ... Explorations winner, an initiative funded by the Bill ... MPH, Professor of Obstetrics, Gynecology and Reproductive Sciences; ... at Temple University School of Medicine will pursue ... titled "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", ...
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... to improve low cost methods for carbon capture. Scientists ... national synchrotron to investigate the efficiency of calcium oxide ... results, published in the journal of Energy & ... the key mechanisms involved. This new knowledge will inform ...
... 2012) -- Using mutant zebra fish, researchers studying the earliest ... gotten a look at a mechanism involved in a genetic ... in the Aug. 1 issue of the journal Development ... scrutiny in future research into Fraser syndrome, a many-faceted and ...
... millennia, humans have pondered their mortality and whether death ... an afterlife. Millions of Americans have reported near-death or ... believe in an afterlife, from reincarnation to resurrection and ... abound, but there has been no comprehensive and rigorous, ...
Cached Biology News:Low-cost carbon capture gets X-rayed 2Low-cost carbon capture gets X-rayed 3Study of zebra fish mouth formation may speak to Fraser syndrome hearing loss 2Study of zebra fish mouth formation may speak to Fraser syndrome hearing loss 3$5 million grant awarded to UC Riverside to study immortality 2$5 million grant awarded to UC Riverside to study immortality 3$5 million grant awarded to UC Riverside to study immortality 4
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Phospho-Cyclin D1 (Thr286) Antibody...
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: